Synosia Therapeutics, Inc.
http://www.synosia.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Synosia Therapeutics, Inc.
Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s
With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.
Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s
With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.
Versant Ventures Looks To Canada, Europe For New Deals
Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”
Biotie Therapies’ Options Expand On Nalmefene And Tozadenant Progress
Finland's only publicly listed biotech, Biotie Therapies, is reviewing its licensing and M&A options in niche CNS areas as product milestone payments and equity investments expand its cash runway.
Company Information
- Other Names / Subsidiaries
-
- Synosis Therapeutics